MorphoSys (MOR) PT Set at €65.00 by Royal Bank of Canada
MOR has been the subject of several other reports. Independent Research set a €104.00 ($120.93) target price on shares of MorphoSys and gave the company a neutral rating in a research note on Wednesday, November 28th. Berenberg Bank set a €108.00 ($125.58) target price on shares of MorphoSys and gave the company a neutral rating in a research note on Thursday, February 28th. Deutsche Bank set a €125.00 ($145.35) target price on shares of MorphoSys and gave the company a buy rating in a research note on Tuesday, January 29th. Goldman Sachs Group set a €114.00 ($132.56) target price on shares of MorphoSys and gave the company a neutral rating in a research note on Monday, December 17th. Finally, JPMorgan Chase & Co. reissued a buy rating on shares of MorphoSys in a research note on Wednesday, December 12th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the stock. MorphoSys presently has an average rating of Hold and a consensus price target of €101.30 ($117.79).
MOR stock opened at €85.90 ($99.88) on Thursday. MorphoSys has a 12 month low of €76.45 ($88.90) and a 12 month high of €124.90 ($145.23). The company has a market cap of $2.71 billion and a P/E ratio of -95.98. The company has a quick ratio of 11.21, a current ratio of 11.51 and a debt-to-equity ratio of 0.01.
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Featured Article: Why is the ex-dividend date different from the record date?
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.